Epstein Secrets

From: ' To: Lesley Groff Subject: Fwd: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:17:36 +0000 Lesley please forward to Jeffrey rs Rony

From: ' To: Lesley Groff Subject: Fwd: FOURIER: Significant LDL Reductio

st, 74 mg/dL). antibodies were reported to develop. Some Takeaways from FOURIER "We've never been able to plumb these depths before." lead author Marc S. Sabatine, MD, of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. "These data strongly suggest that patients ben

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Subject: Fwd: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:18:31 +0000

From: Lesley Groff To: Jeffrey Epstein <[email protected]> Sub

t across quartiles of baseline LDL level (highest, 126 mg/dL to lowest, 74 mg/dL). 'We've never been able to plumb these depths before," lead author Marc S. Sabatine, MD, of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. "These data strongly suggest that patients ben

From: Lesley Groff To: "Dr. Rony + Catherine Shimony" Subject: Re: FOURIER: Significant LDL Reduction with Evolocumab Date: Fri, 24 Mar 2017 11:18:21 +0000 will d

From: Lesley Groff To: "Dr. Rony + Catherine Shimony" Subject: R

ss quartiles of baseline LDL level (highest, 126 mg/dL to lowest, 74 mg/dL). IIr 'We've never been able to plumb these depths before," lead author Marc S. Sabatine, MD. of Brigham and Women's Hospital and Harvard Medical School, said in a conference press release. -These data strongly suggest that patients ben